News Focus
News Focus
icon url

Rubyred77

10/21/17 3:05 AM

#125607 RE: F1ash #125605

par·a·digm shift - a fundamental change in approach or underlying assumptions.

Perfect word to do some DD on when trying to reference timelines using the "old way" things got done.

Thinking a-273 would take 3 more years to gain approval?

I laugh at that assumption.
icon url

jimmy667

10/21/17 3:11 AM

#125608 RE: F1ash #125605

One can see a few parallels to A2-73 and a very stark contrast as well. A2-73 has a lot of quality of life, improvements in daily living reports as well as some quite remarkable improvements ....painter, pianist, golfer, now Can take public transport and Not get lost, resolution of ALZ inducted insomnia, resolution of irritability, increased sociability and many others.
Maybe if there were more emphasis on improving the quality of life rather than blindly focusing on some biomarkers that may not be correlative in improvements in the first place, as in What happened to abeta/tau, then maybe Drug Companies would do a better job of finding drugs to improve quality of life in ALZ patients.

Dr. MacFarlane said something relative to this in his interview.

icon url

frrol

10/21/17 7:32 AM

#125616 RE: F1ash #125605

Helpful, thanks. Always good to remind oneself of the risks in drug development and the importance of large, robust trials to confirm or reject potential signal. 2-73 is promising, but the jury is still out on its viability. Fingers crossed. We have a great shot.
icon url

XenaLives

10/21/17 11:54 AM

#125642 RE: F1ash #125605

Apples to oranges, one of your examples was even pre-AZ patients.

That post has no relevance to what is going on at Anavex.

icon url

seventhwave

10/21/17 4:31 PM

#125684 RE: F1ash #125605

F1ash, useful DD. Another one would be VTVT's compound currently in a late P3 and the next one on deck for readout in AZ space. Their approach of modulation of the RAGE pathway may improve mitochondrial damage. (Not your typical targeting of abeta aggregation or tau tangles.)
I haven't done enough digging to have a stake in this. Ron Perelman is a huge stakeholder. (PS: Moderators, I'm long & strong AVXL & not looking to get bashed / deleted.)
http://www.sciencedirect.com/science/article/pii/S0891584917307281